HC Wainwright Has Negative Outlook of Genmab A/S Q2 Earnings

Key Points

• HC Wainwright has downgraded Genmab A/S's Q2 2026 earnings per share estimate from $0.62 to $0.61, maintaining a "Buy" rating with a $40.00 target price.
• Genmab A/S recently reported earnings of $0.54 per share for the last quarter, exceeding expectations, but with revenue falling short of analysts' predictions at $925 million.
• Despite mixed ratings from analysts, Genmab A/S has a consensus rating of "Moderate Buy" and a price target of $40.80, reflecting varied investor sentiment.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Genmab A/S in a research note issued to investors on Wednesday, October 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.61 per share for the quarter, down from their previous estimate of $0.62. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.66 EPS and FY2026 earnings at $2.26 EPS.

Other equities analysts have also issued reports about the company. Wall Street Zen raised Genmab A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, September 26th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

Genmab A/S Trading Up 0.1%

NASDAQ GMAB opened at $32.75 on Friday. The company has a 50-day moving average price of $27.71 and a two-hundred day moving average price of $23.23. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.65. The stock has a market cap of $21.03 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 1.84 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GMAB. GAMMA Investing LLC raised its position in Genmab A/S by 1,465.3% in the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock worth $656,000 after acquiring an additional 31,343 shares in the last quarter. QRG Capital Management Inc. grew its stake in shares of Genmab A/S by 213.7% in the 1st quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock worth $1,465,000 after purchasing an additional 50,990 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after purchasing an additional 4,666 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Genmab A/S by 20.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock valued at $4,885,000 after purchasing an additional 42,361 shares during the last quarter. Finally, DAVENPORT & Co LLC boosted its holdings in Genmab A/S by 21.1% during the first quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company's stock worth $620,000 after buying an additional 5,529 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.